PRESS RELEASE: CWOW Ventures Tour to provide exposure to the latest ideas in a first-of-its-kind Cambridge life science/biotech showcase
27th May 2025
CWOW Ventures Tour to provide exposure to the latest ideas in a first-of-its-kind Cambridge life science/biotech showcase
We are delighted to share further details of the two-day Ventures Tour, central to the upcoming Cambridge Wide Open Week (CWOW) on 9th-13th June 2025.
This first-of-its-kind investor showcase – which takes place on Monday 9th June and Tuesday 10th June only – will feature a range of portfolio pitch sessions hosted by some of Cambridge’s most prominent venture capital firms, venture builders, incubators, accelerators and business angels.
The event – aimed primarily at angel investors, corporate investors, venture capitalists and financial institutions internal and external to Cambridge – will showcase the pioneering research and game-changing innovations from within the dynamic Cambridge ecosystem, and provide rare venture opportunities in these high-potential, investment-ready startups already revolutionising the biotech and life sciences sectors.
The following portfolio companies will be pitching over the two-day session:
DAY ONE (Monday 9th June 2025)
Amadeus Capital Partners portfolio companies: Constructive Bio (genome writing and engineered translation), Nuclera (rapid protein prototyping), Quibim (imaging through AI Techniques), Inotec AMD (medical equipment), and Charco Neurotech (wearable tech device to ease Parkinson’s).
Stevenage Bioscience Catalyst portfolio companies: Cambridge Medixine (enabling therapeutics with next-gen mRNA technology), MFX (accelerating cell and gene therapy development and manufacturing), Ternary Therapeutics (molecular glue therapeutics), Vasodynamics (patient-friendly, cost-effective medicines to prevent side-effects of anticancer therapies).
Accelerate Cambridge portfolio companies: Chain of Thought (enterprise AI applications), Orca Scan (enterprise barcode solutions), SmileShot (dental imaging through AI-powered automation), eScent (wearable scent technology), Water Sensitive Cambridge (supporting the urban water cycle through nature).
o2h Ventures & Meltwind portfolio companies: Healx/ Meltwind (next-gen AI drug discovery), Vianautis/ Meltwind (nanovesicle platform using advanced polymer materials and machine learning), Vesynta/ o2h Ventures (treatment options for retinal vascular disease), Atelerix/ o2h Ventures (transforming the preservation and transport of biological samples).
Accelerate @Babraham portfolio companies: Appraiseye Limited (AI-powered computer vision for biotech & medicine), Enstic (specialised field machines to simplify insect identification for agricultural/ veterinary health/ public health sectors), Promatix Biosciences Ltd (cancer therapies using bispecific antibodies), Five Alarm Bio (innovative approach to treating the diseases of aging), OvartiX (women’s health drug discovery).
DAY TWO (Tuesday 10th June 2025)
Cambridge Innovation Capital portfolio companies: Immutrin (best-in-class therapeutic antibody for systemic amyloidosis), TRIMTECH (developing targeted protein degradation therapies for neurodegenerative diseases), ArkVax (developing glycoconjugate vaccines), Awen (innovative oncology treatments), Indegra Therapeutics (integrin modulating drugs), RevoNA (RNA targeted drugs), Spirea (ELIVATE linker technology), Verinnogen (cutting edge tools for cancer research), NK:IO (first-generation wNK:IO human NK cells for cancer immunotherapy).
Cambridge Angels portfolio companies: Flit (folding electric bike for commuters), Bugbiome (harnessing natural microbiomes for crop protection), Qureright (accelerating drug development through AI-powered data curation), Techspert (specialist healthcare and life sciences expert network).
Innovate UK Business Growth portfolio companies: Aila Biotech (patented gene delivery technology), Coherence Neuro (formerly Opto Bio) (harnessing bioelectricity and tiny neural implants to treat cancer), PartitionBio (developing proprietary biomolecular condensates for biomedical applications), Zetta Genomics (pioneers in genomics).
Cambridge Enterprise & Park Walk portfolio companies: BioTryp Therapeutics (novel oral antibiofilm therapies for bacterial infections), PharmEnable Therapeutics (small molecule therapeutics for inaccessible targets in the brain and inside the cell), Semarion (Microcarrier Platform to Accelerate Cell Assaying Workflows), Psyomics (a digital front door for Mental Health services), Enhanc3d Genomics (exploring the 3D organisation of DNA in health and disease).
The third Cambridge Wide Open event, organised by Hauxton-based life sciences and technology firm, o2h group, also includes behind-the-scenes tours of Cambridge’s leading science companies and innovation parks, with rare access to the labs, offices and workshops of the technologies of the future. There will also be talks, masterclasses, cutting-edge science conferences, networking receptions and community-driven events for all ages, as well as a biotech bikers event, a community day, and a summer garden party at the o2h group’s HQ at Hauxton House.
o2h co-founder and co-CEO, Prashant Shah said: “The new two-day Venture Tour is an interesting addition to this year’s expanded Cambridge Wide Open Week as it offers promising exposure and investment opportunities for some of the most exciting Cambridge biotech and life science companies. The Tour is open to investors, ecosystem participants and the wider Cambridge community, providing a unique platform spotlighting some of the most innovative and pioneering life sciences, biotech, deeptech, and techbio companies, and giving them the chance to present their ideas.”
For more information go to www.cambridgewideopenweek.com, or visit our official LinkedIn page – Cambridge Wide Open Week. If you are an investor and wish to attend the investors showcase session, then please RSVP at cwow@o2h.com.
About the o2h group:
The o2h group was founded in 2005, with the vision to seed new ideas in life science and technology innovation. The group works across boundaries with a collaborative and shared approach to innovation; therefore, o2h co-invests, co-creates, and co-executes to bring these ideas to life. The divisions include funding, incubation and execution covering chemistry, biology and tech.
The o2h group is co-located in Cambridge, UK and in Ahmedabad, India and has six verticals covering: ventures, discovery, technology, co-work, community and therapeutics.
For more information, please see – www.o2h.com